11 results on '"Booser, Daniel J."'
Search Results
2. Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention.
- Author
-
Mustafayev, Fatma Nihan Akkoc, Liu, Diane D., Gutierrez, Angelica M., Lewis, John E., Ibrahim, Nuhad K., Valero, Vicente, Booser, Daniel J., Litton, Jennifer K., Koenig, Kimberly, Dihua Yu, Sneige, Nour, and Arun, Banu K.
- Subjects
- *
DASATINIB , *ESTROGEN receptors , *BREAST cancer treatment , *BREAST cancer risk factors , *NEEDLE biopsy - Abstract
Objective: Risk-reducing therapy with selective estrogen receptor (ER) modulators and aromatase inhibitors reduce breast cancer risk. However, the effects are limited to ER-positive breast cancer. Therefore, new agents with improved toxicity profiles that reduce the risk in ER-negative breast cancers are urgently needed. The aim of this prospective, short-term, prevention study was to evaluate the effect of dasatinib, an inhibitor of the tyrosine kinase Src, on biomarkers in normal (but increased risk) breast tissue and serum of women at high risk for a second, contralateral primary breast cancer. Materials and Methods: Women with a history of unilateral stage I, II, or III ER-negative breast cancer, having no active disease, and who completed all adjuvant therapies were eligible. Patients underwent baseline fine-needle aspiration (FNA) of the contralateral breast and serum collection for biomarker analysis and were randomized to receive either no treatment (control) or dasatinib at 40 or 80 mg/day for three months. After three months, serum collection and breast FNA were repeated. Planned biomarker analysis consisted of changes in cytology and Ki-67 on breast FNA, and changes in serum levels of insulin-like growth factor 1 (IGF-1), IGF-binding protein 1, and IGF-binding protein 3. The primary objective was to evaluate changes in Ki-67 and secondary objective included changes in cytology in breast tissue and IGF-related serum biomarkers. Toxicity was also evaluated. Results: Twenty-three patients started their assigned treatments. Compliance during the study was high, with 86.9% (20/23) of patients completing their assigned doses. Dasatinib was well tolerated and no drug-related grade 3 and 4 adverse events were observed. Since only one patient met the adequacy criteria for the paired FNA sample, we could not evaluate Ki-67 level or cytological changes. No significant change in serum biomarkers was observed among the three groups. Conclusion: Dasatinib was well tolerated but did not induce any significant changes in serum biomarkers. The study could not fulfill its primary objective due to an inadequate number of paired FNA samples. Further, larger studies are needed to evaluate the effectiveness of Src inhibitors in breast cancer prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer.
- Author
-
Nelson, Blessie Elizabeth, Saleem, Sadia, Damodaran, Senthil, Somaiah, Neeta, Piha‐Paul, Sarina, Moore, Julia Ann, Yilmaz, Bulent, Ogbonna, Deby, Karp, Daniel D., Dumbrava, Ecaterina, Tsimberidou, Apostolia M., Hong, David S., Rodon Ahnert, Jordi, Milton, Denái R., Zheng, Xiaofeng, Booser, Daniel J., Ibrahim, Nuhad K., Conley, Anthony P., Bhosale, Priya, and Rojas Hernandez, Cristhiam M.
- Subjects
- *
TRIPLE-negative breast cancer , *ERIBULIN , *CANCER patients , *BREAST tumors , *ADVERSE health care events - Abstract
Background: Selinexor (KPT‐330) is a potent inhibitor of exportin 1 (XPO1), in turn inhibiting tumor growth. Selinexor enhances the antitumor efficacy of eribulin in triple‐negative breast cancer (TNBC) in vitro and in vivo. Given the unmet medical need in TNBC and sarcoma, the authors explored the safety and efficacy of this combination. Methods: The authors conducted a phase 1b trial of combined selinexor and eribulin using a 3 + 3 dose‐escalation design in patients who had advanced solid tumors and in those who had TNBC in a dose‐expansion cohort. Results: Patients with TNBC (N = 19), sarcoma (N = 9), and other cancers (N = 3) were enrolled in the dose‐escalation cohort (N = 10) and in the dose‐expansion cohort (N = 21). The median number lines of prior therapy received was four (range, from one to seven prior lines). The most common treatment‐related adverse events for selinexor were nausea (77%), leukopenia (77%), anemia (68%), neutropenia (68%), and fatigue (48%). One dose‐limiting toxicity occurred at the first dose level with prolonged grade 3 neutropenia. The recommended phase 2 dose was 80 mg of selinexor orally once per week and 1 mg/m2 eribulin on days 1 and 8 intravenously every 3 weeks. The objective response rate (ORR) was 10% in three patients. In the dose‐escalation cohort, the ORR was 10%, whereas six patients with had stable disease. In the TNBC dose‐expansion cohort (n = 18), ORR was 11%, and there were two confirmed partial responses with durations of 10.8 and 19.1 months (ongoing). Conclusions: Selinexor and eribulin had an acceptable toxicity profile and modest overall efficacy with durable responses in select patients. Plain Language Summary: Effective therapies for advanced, triple‐negative breast cancer and sarcoma represent an unmet need.Exportin 1 is associated with the transport of cancer‐related proteins.Preclinical studies have demonstrated tumor growth inhibition and enhanced tumor sensitivity in patients who receive selinexor combined with eribulin.In this phase 1b study, the authors evaluated the safety profile and clinical activity of the combination of selinexor, a potent oral inhibitor of exportin 1, and eribulin in patients with advanced cancers enriched for triple‐negative breast cancer or sarcoma.The combination was well tolerated; most adverse events were mild or moderate, reversible, and managed with dose modifications or growth factor support.The combination of selinexor and eribulin produced an antitumor response, particularly in some patients with triple‐negative breast cancer.This work lays the foundation for prospective investigations of the role of selinexor and eribulin in the treatment of triple‐negative breast cancer. Combined selinexor and eribulin was safe, with a manageable toxicity profile and modest overall clinical efficacy. Durable responses and disease control were observed in patients who had metastatic, triple‐negative breast cancer. Further study is needed to examine the determinants of response to this combination. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
- Author
-
Lim, Bora, Murthy, Rashmi K., Lee, Jangsoon, Jackson, Summer A., Iwase, Toshiaki, Davis, Darren W., Willey, Jie S., Wu, Jimin, Shen, Yu, Tripathy, Debu, Alvarez, Ricardo, Ibrahim, Nuhad K., Brewster, Abenaa M., Barcenas, Carlos H., Brown, Powel H., Giordano, Sharon H., Moulder, Stacy L., Booser, Daniel J., Moscow, Jeffrey A., and Piekarz, Richard
- Abstract
Background: Human epidermal growth factor 2 (HER2) is an effective therapeutic target in breast cancer; however, resistance to anti-HER2 agents such as trastuzumab and lapatinib develops. In a preclinical model, an HDAC inhibitor epigenetically reversed the resistance of cancer cells to trastuzumab and showed synergistic efficacy with lapatinib in inhibiting growth of trastuzumab-resistant HER2-positive (HER2+) breast cancer.Methods: A phase 1b, dose escalation study was performed to assess maximum tolerated dose, safety/toxicity, clinical efficacy and explored pharmacodynamic biomarkers of response to entinostat combined with lapatinib with or without trastuzumab.Results: The combination was safe. The MTD was lapatinib, 1000 mg daily; entinostat, 12 mg every other week; trastuzumab, 8 mg/kg followed by 6 mg/kg every 3 weeks. Adverse events included diarrhoea (89%), neutropenia (31%), and thrombocytopenia (23%). Neutropenia, thrombocytopenia and hypokalaemia were noted. Pharmacodynamic assessment did not yield conclusive results. Among 35 patients with evaluable response, PR was observed in 3 patients and CR in 3 patients, 1 maintained SD for over 6 months.Discussion: This study identified the MTD of the entinostat, lapatinib, and trastuzumab combination that provided acceptable tolerability and anti-tumour activity in heavily pre-treated patients with HER2+ metastatic breast cancer, supporting a confirmatory trial. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
5. Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases.
- Author
-
Eckmann, Karen, Michaud, Laura B, Rivera, Edgardo, Madden, Timothy L, Esparza-Guerra, Laura, Kawedia, Jitesh, Booser, Daniel J, Green, Marjorie C, Hortobagyi, Gabriel N, and Valero, Vicente
- Subjects
- *
ALKALINE phosphatase , *AMINOTRANSFERASES , *BILIRUBIN , *BREAST tumors , *CONFIDENCE intervals , *LIVER , *LIVER tumors , *METASTASIS , *RESEARCH funding , *STATISTICS , *DOCETAXEL , *PILOT projects , *DATA analysis software , *DESCRIPTIVE statistics - Abstract
Background: Limited clinical data are available regarding the safety of docetaxel in metastatic breast cancer patients with liver dysfunction. Methods: Eligible patients had breast cancer with impaired liver function secondary to hepatic metastases and were candidates for docetaxel therapy. They were assigned to one of five groups on the basis of total bilirubin, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels. All other causes of liver dysfunction were excluded, and bile duct obstruction was corrected, if possible, prior to study entry. Patients received docetaxel every three weeks. The chemotherapy dose was chosen on the basis of the patient’s level of hepatic dysfunction and escalated as tolerated. The primary outcome of this study was safety. The secondary outcomes were pharmacokinetic data and efficacy in terms of time to disease progression. Results: Twenty-three patients were enrolled. No unexpected toxicities occurred. Grade 3/4 fatigue (65%), neutropenia (30%), myalgias (26%), neutropenic fever (26%), vomiting (9%), and rash (9%) were the most common serious adverse events. The median time to progression was three months (range 1–18 months). Pharmacokinetic results indicated that patients with more severe hepatic dysfunction may have been underdosed based on our conservative dosing strategy. Conclusions: Docetaxel can be administered to patients with metastatic breast cancer and liver dysfunction after dose attenuation. However, because of a narrow therapeutic index in this clinical setting, therapy should be closely monitored with subsequent dose escalation when possible. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy.
- Author
-
Skinner, Heath D., Strom, Eric A., Motwani, Sabin B., Woodward, Wendy A., Green, Marjorie C., Babiera, Gildy, Booser, Daniel J., Meric-Bernstam, Funda, and Buchholz, Thomas A.
- Subjects
- *
CANCER patients , *BREAST cancer surgery , *CANCER treatment , *MASTECTOMY , *DRUG therapy - Abstract
Background: Radiation is a standard component of treatment for patients with locoregional recurrence (LRR) of breast cancer following mastectomy. The current study reports the results of a 10% radiation dose escalation in these patients. Methods: 159 patients treated at MD Anderson Cancer Center between 1994-2006 with isolated LRR after mastectomy alone were reviewed. Patients in the standard treatment group (65 pts, 40.9%) were treated to 50 Gy comprehensively plus a boost of 10 Gy. The dose escalated group (94 pts, 59.1%) was treated to 54 Gy comprehensively and a minimum 12 Gy boost. Median dose in the standard dose and dose escalated group was 60 Gy (±1 Gy, 95% CI) and 66 Gy (±0.5 Gy, 95% CI) respectively. Median follow up for living patients was 94 months from time of recurrence. Results: The actuarial five year locoregional control (LRC) rate was 77% for the entire study population. The five year overall survival and disease-free survival was 55% and 41%, respectively. On multivariate analysis, initial tumor size (p = 0.03), time to initial LRR (p = 0.03), absence of gross tumor at the time of radiation (p = 0.001) and Her2 status (p = 0.03) were associated with improved LRC. Five year LRC rates were similar in patients with a complete response to chemotherapy without surgery and patients with a complete surgical excision (77% vs 83%, p = NS), compared to a 63% LRC rate in patients with gross disease at the time of radiation (p = 0.024). LRC rates were 80% in the standard dose group and 75% in the dose escalated group (p = NS). Conclusions: While LRR following mastectomy is potentially curable, distant metastasis and local control rates remain suboptimal. Radiation dose escalation did not appear to improve LRC. Given significant local failure rates, these patients are good candidates for additional strategies to improve their outcomes [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
7. A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer.
- Author
-
Hatzis, Christos, Pusztai, Lajos, Valero, Vicente, Booser, Daniel J., Esserman, Laura, Lluch, Ana, Vidaurre, Tatiana, Holmes, Frankie, Souchon, Eduardo, Hongkun Wang, Martin, Miguel, Cotrina, José, Gomez, Henry, Hubbard, Rebekah, Chacón, J. Ignacio, Ferrer-Lozano, Jaime, Dyer, Richard, Buxton, Meredith, Yun Gong, and Yun Wu
- Subjects
- *
GENOMICS , *ANTHRACYCLINES , *DRUG therapy , *BREAST cancer treatment , *CANCER relapse , *BIOPSY , *THERAPEUTICS - Abstract
The article discusses a study of a genomic predictor of response and survival following sequential taxane and anthracycline chemotherapy for newly diagnosed ERBB2-negative breast cancer conducted at the M. D. Anderson Cancer Center (MDACC) in Houston, Texas from June 2011 to March 2010. Higher-risk patients who were clinically lymph node-positive at presentation were included to determine the signature of chemoresistance. Fine-needle aspiration and core biopsy were used to obtain 227 biopsy samples. Results show that the link between predicted treatment sensitivity and distant relapse-free survival (DRFS) is not related to the taxane therapy administered. Also cited is the significant association between genomic predictions and risk of distant relapse or death.
- Published
- 2011
- Full Text
- View/download PDF
8. A Phase 2 Study of A Fixed Combination of Uracil and Ftorafur (UFT) and Leucovorin Given Orally in A 3-times-daily Regimen to Treat Patients With Recurrent Metastatic Breast Cancer.
- Author
-
Hortobagyi, Gabriel N., Helm, William, Hutchins, Laura, Rivera, Edgardo, Mason, Bernard, Booser, Daniel J., and Kirshner, Jeffrey
- Subjects
- *
CLINICAL trials , *URACIL , *FOLINIC acid , *ANTHRACYCLINES , *BREAST cancer patients - Abstract
The article reports on the Phase 2 study of combination therapy using Uracil and Ftorafur (UFT) and Leucovorin for patients with recurrent metastatic breast cancer. It notes that the patients previously treated with anthracyclines were given the three-times-daily combination treatment administered orally. It implies that the combined therapy using UFT and leucovorin was found to manage the grade 3 toxicities in patients with metastatic breast cancer.
- Published
- 2010
- Full Text
- View/download PDF
9. Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy.
- Author
-
Brewster, Abenaa M., Hortobagyi, Gabriel N., Broglio, Kristine R., Shu-Wan Kau, Santa-Maria, Cesar A., Arun, Banu, Buzdar, Aman U., Booser, Daniel J., Valero, Vincente, Bondy, Melissa, and Esteva, Francisco J.
- Subjects
- *
BREAST cancer , *PROGNOSTIC tests , *BREAST cancer patients , *ADJUVANT treatment of cancer , *CELL receptors , *DIAGNOSIS - Abstract
There is limited prognostic information to identify breast cancer patients who are at risk for late recurrences after adjuvant or neoadjuvant systemic therapy (AST). We evaluated the residual risk of recurrence and prognostic factors of 2838 patients with stage I-III breast cancer who were treated with AST between January 1, 1985, and November 1, 2001, and remained disease free for 5 years. Residual recurrence-free survival was estimated from the landmark of 5 years after AST to date of first recurrence or last follow-up using the Kaplan-Meler method. The log-rank test (two-sided) was used to compare groups. Residual recurrence-free survival rates at 5 and 10 years were 89% and 80%, respectively, and 216 patients developed a recurrence event. The 5-year residual risks of recurrence for patients with stage I, II, and Ill cancers were 7% (95% confidence interval [Cl] = 3% to 15%), 11% (95% Cl = 9% to 13%), and 13% (95% Cl = 10% to 17%), respectively (P = .02). In multivariable analysis, stage, grade, hormone receptor status, and endocrine therapy were associated with late recurrences. Breast cancer patients have a substantial residual risk of recurrence, and selected tumor characteristics are associated with late recurrences. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
10. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation.
- Author
-
Ibrahim, Nuhad K., Valero, Vicente, Rahman, Zia, Theriault, Richard L., Walters, Ronald S., Buzdar, Aman U., Booser, Daniel J., Holmes, Frankie A., Murray, James L., Willey, Jie, Bast, Robert, Hortobagyi, Gabriel N., Ibrahim, N K, Valero, V, Rahman, Z, Theriault, R L, Walters, R S, Buzdar, A U, Booser, D J, and Holmes, F A
- Subjects
- *
BREAST cancer , *TOXICOLOGY , *DOSAGE forms of drugs - Abstract
Vinorelbine (Navelbine) has significant activity against breast carcinoma and is less neurotoxic than vinblastine. Because vinblastine has improved activity when administered by continuous infusion, we conducted a Phase I-II study to determine the maximum tolerated dose (MTD) of vinorelbine when given by continuous infusion and the response rates to it in heavily pretreated metastatic breast cancer patients. Between April 1994 and August 1997, 87 patients were entered in the study. All were female and had proven metastatic breast cancer. Ninety-five percent of them had received prior doxorubicin treatment, and 74% had received prior paclitaxel treatment. In Phase I of the study, all patients received 8 mg of vinorelbine by intravenous (i.v.) bolus followed by a continuous infusion of vinorelbine over 96 hr. When the MTD was determined, patients were entered in the Phase II arm to assess treatment responses and cumulative toxic reactions. In the Phase I arm (43 patients, 182 cycles), we determined the MTD of vinorelbine to be 8 mg by i.v. bolus followed by a continuous infusion of 11 mg/m2/day over 4 days. The dose-limiting toxic reaction was grade 3-4 granulocytopenia in 35% of the cycles and neutropenic fever in 15% of the cycles. Forty-four patients (193 cycles) were treated at the MTD. Seven (16%) of them had a response (2 complete responses, 5 partial responses). The median durations of response and survival were 4.3 and 8.6 months, respectively. However, cumulative toxic reactions (neutropenic fever and stomatitis) in 22 patients (50%) required dose reductions. A continuous infusion of vinorelbine can be safely administered but with a narrow therapeutic index because of cumulative toxic reactions. We recommend a modified MTD of vinorelbine: 8 mg by i.v. bolus followed by a continuous infusion of 10 mg/m2/day over 4 days. However, this treatment schedule offers no apparent advantage over the commonly used weekly vinorelbine schedule. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
11. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.
- Author
-
Hortobagyi, Gabriel N., Buzdar, Aman U., Theriault, Richard L., Valero, Vicente, Frye, Debra, Booser, Daniel J., Holmes, Frankie A., Giralt, Sergio, Khouri, Issa, Andersson, Borje, Gajewski, James L., Rondon, Gabriela, Smith, Terry L., Singletary, Sonja E., Ames, Frederick C., Sneige, Nour, Strom, Eric A., McNeese, Marsha D., Deisseroth, Albert B., and Champlin, Richard E.
- Subjects
- *
AUTOGRAFTS , *BREAST cancer , *DRUG therapy - Abstract
Background: Uncontrolled studies have reported encouraging outcomes for patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support. We conducted a prospective randomized trial to compare standard-dose chemotherapy with the same therapy followed by high-dose chemotherapy.Patients and Methods: Patients with 10 or more positive axillary lymph nodes after primary breast surgery or patients with four or more positive lymph nodes after four cycles of primary (neoadjuvant) chemotherapy were eligible. All patients were to receive eight cycles of 5-fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC). Patients were stratified by stage and randomly assigned to receive two cycles of high-dose cyclophosphamide, etoposide, and cisplatin with autologous hematopoietic stem cell support or no additional chemotherapy. Tamoxifen was planned for postmenopausal patients with estrogen receptor-positive tumors and chest wall radiotherapy was planned for all. All P values are from two-sided tests.Results: Seventy-eight patients (48 after primary surgery and 30 after primary chemotherapy) were registered. Thirty-nine patients were randomly assigned to FAC and 39 to FAC followed by high-dose chemotherapy. After a median follow-up of 6.5 years, there have been 41 relapses. In intention-to-treat analyses, estimated 3-year relapse-free survival rates were 62% and 48% for FAC and FAC/high-dose chemotherapy, respectively (P =.35), and 3-year survival rates were 77% and 58%, respectively (P =.23). Overall, there was greater and more frequent morbidity associated with high-dose chemotherapy than with FAC; there was one septic death associated with high-dose chemotherapy.Conclusions: No relapse-free or overall survival advantage was associated with the use of high-dose chemotherapy, and morbidity was increased with its use. Thus, high-dose chemotherapy is not indicated outside a clinical trial. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.